DOI: https://doi.org/10.26641/2307-0404.2018.2.133696

Modern tactics of managing patients with pulmonary arterial hypertension associated with systemic connective tissue diseases.

O. O. Khaniukov, L. I. Vasylieva, Ye. D. Yehudina, O. S. Kalashnykova

Abstract


A review of the literature on the problem of one of the rare manifestations of systemic diseases - pulmonary arterial hypertension is presented. The necessity of early and thorough differential diagnosis, verification of the diagnosis using invasive methods for assessing central hemodynamics is substantiated. A model for screening patients with systemic scle­roderma, which simplifies the determination of indications to set the research methods that allow to verify the diagnosis is proposed. Modern approaches to drug therapy are described, and questions of improving the patients’ survival with this prognostically unfavorable pathology are discussed.


Keywords


pulmonary arterial hypertension; systemic connective tissue diseases; systemic scleroderma

References


Syniachenko OV, Yehudina YeD, Mikukst VYa, Yermolaiva MV, et al. [Angiopathy in systemic scle­roderma]. Ukrainskyi revmatolohichnyi zhurnal. 2017;67(1):5-12. Russian.

Volkov AV. [Diagnosis of pulmonary hyper­tension in systemic scleroderma]. Sovremenaya revmato­logiya. 2008;4:22-25. Russian.

Van den Hoogen F, Khanna D, Fransen J, [et al.] 2013 classification criteria for systemic sclerosis: anAme­ricanCollegeof Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. 2013;72(11):1747–55. doi: 10.1136/annrheumdis-2013-204424

Syniachenko OV, Yehudina YeD, Mikukst VYa, Yermolaiva MV. [Rheological properties of blood serum in limited and diffuse forms of systemic scleroderma]. Ukrainskyi zhurnal dermatolohii, venerolohii, kosmeto­lohii. 2017;64(1):43-46. Russian.

Saad YeO, Ananeva LP, Novikova DS, Ajkepe­rova RT. [Traditional risk factors for cardiovascular disease in systemic scleroderma and their relationship with heart structural changes]. Nauchno-prakticheskaya revmatologiya.2016;54(6):687-692. Russian.

MathaiSC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary ar­terial hypertension. Eur Respir J.2007; 29:469-75.

Francesco B, Franchini S, Colantuoni E, et al. Anti-β2 glycoprotein I antibodies are independently associated with macrovascular disease and mortality in scleroderma patients Arthritis Rheum. 2009;60(8):2480-89. doi: 10.1002/art.24684.

Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a Referral Centre. Eur Respir J. 2012;39(4):945-55. doi: 10.1183 / 09031936.00078411

Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic scle­rosis as a unique phenotype. Chest. 2010;138(6):1383-94. doi: 10.1378/chest.10-0260

Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007-10.

Gü nther S, Jais X, Maitre S, et al. Computed to­mography find- ings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pul­monary hypertension. Arthritis Rheum. 2012;64(9):2995-3005. doi: 10.1002 / art.34501

Denton CP. Systemic sclerosis: from pathogenesis to targeted therapy. Clin. Exp. Rheumatol. 2015;33(4):3-7.

Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792-800. doi: 10.1002/art.21433

Mukerjee D, St George D, Knight C, et al. Echo­cardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004;43(4):461-6. doi: 10.1093/rheumatology/keh067.

Ranchoux B, Harvey LD, Ayon RJ, et al. Endo­the­lial dysfunction in pulmonary arterial hypertension: an evo­lving landscape. Pulm Circ. 2018;8(1):2045893217752912. doi: 10.1177/2045893217752912

McMahan ZH, Cottrell TR, Wigley FM, et al.Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells. Arthritis Rheumatol. 2016;68(10):2540-9. doi: 10.1002/art.39743

Coghlan JC, Denton CP, Grü nig E, et al. Evi­dence-based detec- tion of pulmonary arterial hyper­tension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-9. doi: 10.1136/annrheum­dis-2013-203301

Ho YY, Lagares D, Tager AM, Kapoor M Fib­rosis – a lethal component of systemic sclerosis. Nat. Rev. Rheu­matol. 2014;10(7):390-402. doi: 10.1038/nrrheum.2014.53

Dorfmuller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmo­nary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007;38(6):893-902. doi: 10.1016/j.humpath.2006.11.022

Campo A,MathaiSC, Le Pavec J, et al. Hemo­dynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2016;182(2):252-60. doi: 10.1164/rccm.200912-1820OC

Allanore Y, Borderie D, Avouac J, Zerkk D, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as in­dependent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008;58(1):284-291. doi: 10.1002/art.23187

Huber LC, Bye H, Brock M. The pathogenesis of pulmonary hypertension--an update. Swiss Society of Pul­monary Hypertension.Swiss Med Wkly. 2015;145:14202. doi: 10.4414/smw.2015.14202

GadreSK, Minai OA, Wang XF, et al. Lung or Heart-Lung Transplant in Pulmonary Arterial Hypert­ension: What Is the Impact of Systemic Sclerosis? Exp Clin Transplant. 2017;15(6):676-684. doi: 10.6002 / ect.2016.0209

Badesch DB, McGoon MD, Barst RJ, et al. Lon­gterm survival among patients with scleroderma-as­sociated pulmonary arterial hypertension treated with in­travenous epoprostenol. J Rheumatol. 2009;36(10):2244-9. doi: 10.3899/jrheum.081277

Mathai SP, Hassoun PM. Pulmonary arterial hy­pertension in connective tissue diseases. Heart Fail Clin. 2012;8(3):413-25. doi: 10.1016/j.hfc.2012.04.001

Manetti M, Guiducci S, Matucci-Cerinic M. The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem? Arthritis Res. Ther. 2016;18(5);36-46. doi: 10.1186/s13075-016-0937-x

Launay D, Mouthon L, Hachulla E, et al. Pre­valence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol. 2007;34(5):1005-11.

Mukerjee D, St George D, Coleiro B, [et al]. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088-93.

Avouac J, Airo P, Meune C, Beretta L, et al. Pre­va­lence of pulmonary hypertension in systemic sclerosis in Eu­ropean Caucasians and meta-analysis of 5 studies. J Rheu­matol. 2010;37(11):2290-8. doi: 10.3899/jrheum.100245

Connoly MJ, Abdullah S, Ridout DA, et al. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic scler­osis-pulmonary arterial hypertension. Rheumatology (Oxford). 2017;56(12):2197-203. doi: 10.1093/rheumato­logy/kex351

Badesch DB, Raskob GE, Elliott CG, Krichman AM, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-87. doi: 10.1378/chest.09-1140

Humbert M, Sitbon O, Chaouat A, et al. Pulmo­nary arterial hypertension inFrance: results from a na­tional registry. Am. J. Respir. Crit. Care Med. 2006;173(9):1023-30.

Hayato A, Konno T, Motohiko A, et al. Pulmona­ry hypertension associated with venoocclusive disease in systemic sclerosis: Insight into the mechanism of resistance to vasodilator. Journal of Cardiology Cases. 2012;5(1):e44-e47.

Iudici M, Codullo V, Giuggioli D, et al. Pulmo­nary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clin Exp Rheumatol. 2013;31(76):31-6.

MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheuma­tology (Oxford). 2001;40:453-9.

Boucly A1, Girerd B1, Bourlier D1, et al. Pulmo­nary veno-occlusive disease Rev Mal Respir. 2018;35(2):160-70. doi: 10.1016/j.rmr.2017.11.005

Daraban AM, Enache R, Predescu L, et al. Pul­monary veno-occlusive disease: a rare cause of pul­monary hypertension in systemic sclerosis. Case pre­sentation and review of the literature. Rom J Intern Med. 2015;53(2):175-83.

Johnson SR, Patsios D, Hwang DM, Granton JT. Pulmonary venoocclusive disease and scleroderma asso­ciated pulmonary hypertension. J Rheumatol. 2006;33(11):2347-50.

Williams M, Handler C, Akram R, et al. Role of N- terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur. Heart J. 2006;27(12):1485-94.

Rosenkranz S, Ioana R. Right heart cathe­terisation: best practice and pitfalls in pulmonary hy­pertension Preston European Respiratory Review. 2015;24:642-52. doi: 10.1183 / 16000617.0062-2015

Schwaiger JP, Khanna D, Gerry Coghlan J. Screening patients with scleroderma for pulmonary ar­terial hypertension and implications for other at risk populations. Eur Respir Rev. 2013;22(130):515-25. doi: 10.1183/09059180.00006013

Tsou PS, Rabquer BJ, Ohara RA, et al. Sclero­der­ma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. Rheu­matology. 2016;55(4):745-754. doi: 10.1093/rheumatology/kev399

Dimitroulas T, Sarafidis P, Roma V, et al. Scle­roderma renal crisis accompanied by new-onset pul­monary arterial hypertension: an acute systemic endo­thelial injury? Case report and literature. Inflamm. Allergy Drug. Targets. 2010;9(4);313-318.

Njaman W, Iesaki T, Iwama Y, et al. Serum uric acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. Inter. Heart J.2007;48(4):523-32.

Ami A Shah, Fredrick M Wigley, Laura K. Hum­mers.Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension. J Rheu­matol. 2010;37(1):98-104. doi: 10.3899/jrheum.090697

Steen V, Medsger TA Jr. Predictors of isolated pulmonary hyper- tension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516-22. doi: 10.1002 / art.10775

Gü ndü z OH, Fertig N, Lucas M, Medsger TA. Systemic sclerosis with renal crisis and pulmonary hy­pertension: a report of eleven cases. Arthritis Rheum. 2001;44(7):1663-6.

Forfia PR1, Fisher MR, Mathai SC, et al. Tri­cuspid annular displacement predicts survival in pul­monary hypertension. Am J Respir Crit Care Med 2006;174(9):1034-41.

Kawut SM, Horn EM, Berekashvili KK, et al. Von Willibrand factor independently predicts long-term pulmonary arterial hypertension. Chest. 2005;128:2355-62.


GOST Style Citations


  1. Ангиопатия при системной слеродермии / О.В. Синяченко, Е.Д. Егудина, В.Я. Микукстс, М.В. Ермолаева [и др.] // Укр. ревматол. журнал. –2017. – Т. 67, № 1. – С. 5-12.
  2. Волков А.В. Диагностика легочной гипертен­зии при системной склеродермии // А.В. Волков / Соврем. ревматол. – 2008. – № 4. – С. 22-25.
  3. 2013 classification criteria for systemic sclerosis: an AmericanCollegeofRheumatology/European League Against Rheumatism Collaborative Initiative/ F. Van den Hoogen, D. Khanna, J. Fransen [et al.] // Ann. Rheum. Dis. – 2013. – Vol. 72, N 11. – P. 1747-1755.
  4. Реологические свойства сыворотки крови при лимитированной и диффузной формах системной склеродермии / О.В. Синяченко, В.Я. Микукстс, М.В. Ермолаева, Е.Д. Егудина // Укр. журнал дерма­тології, венерології, косметології. – 2017. – Т. 64, № 1. – C. 43-46.
  5. Традиционные факторы риска сердечно-сосу­дистых заболеваний при системной склеродермии и их связь со структурными изменениями сердца / Е.О. Саад, Л.П. Ананьева, Д.С. Новикова, Р.Т. Алек­перов // Науч.-практ. ревматол. – 2016. – Т. 54, № 6. – С. 687-692.
  6. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension / S.C. Mathai, R.E. Gir­gis, M.R. Fisher [et al.] // Eur. Respir J. – 2007. – Vol. 29. –  P. 469-475.
  7. Anti-β2 glycoprotein I antibodies are indepen­dently associated with macrovascular disease and mor­tality in scleroderma patients / B. Francesco, S. Fran­chini, E. Colantuoni [et al.]//Arthritis Rheum. – 2009. – Vol. 60, N 8. – P. 2480-2489. 
  8. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a Referral Centre / J. Hurdman, R. Condliffe, C.A. Elliot [et al.] // Eur. Respir. J. – 2012. – Vol. 39, N 4. – P. 945-955.
  9. Characterization of connective tissue disease-as­sociated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype / L. Chung, J. Liu, L. Parsons [et al.] // Chest. – 2010. – Vol. 138, N 6. – Р. 1383-1394.
  10. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension / M.M. Hoeper, C. Faulenbach, H. Golpon [et al.] // Eur. Resp. J. – 2004. – Vol. 24.  – P. 1007-1010.
  11. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension / S. Gü nther, X. Jais, S. Maitre  [et al.] // Arthritis Rheum. – 2012. – Vol. 64, N 9. – P. 2995-3005.
  12. Denton C.P. Systemic sclerosis: from pathoge­nesis to targeted therapy / C.P. Denton //Clin. Exp. Rheum. – 2015. – Vol. 33, N 4. – P. 3-7.
  13. Early detection of pulmonary arterial hyper­tension in systemic sclerosis: a French nation- wide prospective multicenter study / E. Hachulla, V. Gressin, L. Guillevin [et al.] // Arthritis Rheum. – 2005. –Vol. 52, N 12. – P. 3792-3800.
  14. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis / D. Mukherjee, D.St. George, C. Knight [et al.] // Rheumatology (Oxford). — 2004. — Vol. 43, N 4. – P. 461-466.
  15. Endothelial dysfunction in pulmonary arterial hy­pertension: an evolving landscape / B. Ranchoux, L.D. Harvey, R.J. Ayon [et al.] // Pulm. Circ. – 2018. –Vol. 8, N 1. – P. 2045893217752912.
  16. Enrichment of Scleroderma Vascular Disease-As­sociated Autoantigens in Endothelial Lineage Cells / Z.H. McMahan, T.R. Cottrell, F.M. Wigley [et al.] // Arthritis Rheum. – 2016. – Vol. 68, N 10. – P. 2540-2549.
  17. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study / J.C. Coghlan, C.P. Denton,E. Grünig[et al.] // Ann. Rheum. Dis. – 2014. – Vol. 73, N 7. – P. 1340-1349.
  18. Fibrosis – a lethal component of systemic scle­rosis / Y.Y. Ho, D. Lagares, A.M. Tager, M. Kapoor // Nat. Rev. Rheum. – 2014. – Vol. 10, N 7. – P. 390-402.
  19. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases / P. Dorfmuller, M. Humbert, F. Perros [et al.] // Hum. Pathol. – 2007. – Vol. 38, N 6. – P. 893-902.
  20. Hemodynamic predictors of survival in scle­ro­derma-related pulmonary arterial hypertension / A. Cam­po, S.C. Mathai, J. Le Pavec [et al.] // Am. J. Resp. Crit. Care Med. – 2016. – Vol. 182, N 2 – P. 252-260.
  21. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis / Y. Allanore, D. Borderie, J. Avouac, D.Zerkak [et. al.] // Arthritis Rheum. – 2008.– Vol. 58, N 1. – P. 284-291
  22. Huber L.C. The pathogenesis of pulmonary hy­pertension--an update / L.C. Huber, H. Bye, M. Brock // Swiss Society Pulmonary Hypertension. Swiss Med Wkly. – 2015. – Vol. 145. – P. 14202.
  23. Lung or Heart-Lung Transplant in Pulmonary Ar­terial Hypertension: What Is the Impact of Systemic Sclerosis? / S.K .Gadre, O.A. Minai, X.F. [et al] // Exp. Clin. Transplant. – 2017. – Vol. 15, N 6. – P. 676-684.
  24. Longterm survival among patients with scle­roderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol / D.B. Badesch, M.D. McGoon, R.J. Barst [et al.] // J. Rheum. – 2009. – Vol. 36, N 10. – P. 2244-2249.
  25. Mathai S.P. Pulmonary arterial hypertension in connective tissue diseases / S.P. Mathai, P.M. Hassoun Heart Fail Clin. – 2012. – Vol. 8, N 3. – P. 413-425.
  26. Manetti M. The crowded crossroad to angioge­nesis in systemic sclerosis: where is the key to the problem? / M. Manetti,S. Guiducci, M. Matucci-Cerinic // Arthritis Res. Ther. – 2016. – Vol. 18, N 5. – P. 36-46.
  27. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease / D. Launay, L. Mouthon, E. Hachulla [et al.] // J. Rheum. – 2007. – Vol. 34, N 5. –P. 1005-1011.
  28. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of registry approach / D. Mukherjee,D. St George, B. Coleiro [et al.] // Ann. Rheum. Dis. – 2003. – Vol. 62, N 11. – P. 1088-9333.
  29. Prevalence of pulmonary hypertension in sys­temic sclerosis in European Caucasians and meta- ana­lysis of 5 studies / J. Avouac, P. Airo, C. Meune, L. Beretta [et al.] // J. Rheum. – 2010. – Vol. 37, N 11. – P. 2290-2298.
  30. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension / M.J. Connolly, S. Abdullah, D.A. Ridout, B.E. Schreiber [et al.] // Rheu­matology (Oxford). – 2017. – Vol. 56, N 12. – P. 2197-2203.
  31. Pulmonary arterial hypertension: baseline cha­racteristics from the REVEAL Registry / D.B. Badesch, G.E. Raskob, C.G. Elliott, A.M. Krichman [et al.] // Chest. – 2010. – Vol. 137, N 2. – P. 376-387.
  32. Pulmonary arterial hypertension inFrance: results from a national registry / M. Humbert, O. Sitbon, A. Cha­ouat [et al.] // Am. J. Resp. Crit. Care Med. – 2006. – Vol. 173, N 9. – P. 1023-1030.
  33. Pulmonary hypertension associated with veno­occlusive disease in systemic sclerosis: Insight into the mechanism of resistance to vasodilator / A. Hayato, T. Konno, A. Motohiko [et al.] // J. Cardiol. Cases. – 2012. – Vol. 5, N 1. – P. e44-e47.
  34. Pulmonary hypertension in systemic sclerosis: pre­valence, incidence and predictive factors in a large multicentric Italian cohor / M. Iudici, V. Codullo, D. Giug­gioli [et al.] // Clin. Exp. Rheum. – 2013. – Vol. 31, N 76. – P. 31-36.
  35. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival / A.J. MacGregor, R.  Canavan, C. Knight [et al.] // Rheu­matology (Oxford). – 2001. – Vol. 40. – P. 453-459.
  36. Pulmonary veno-occlusive disease / A. Boucly, B. Girerd, D. Bourlier [et al.] // Rev. Mal. Respir. – 2018. – Vol. 35, N 2. – P. 160-170.
  37. Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension in systemic sclerosis. Case presentation and review of the literature / A.M. Da­raban, R. Enache, L. Predescu [et al.] // Rom. J. Inter. Med. – 2015. – Vol. 53, N 2. – P. 175-183.
  38. Pulmonary venoocclusive disease and sclero­derma associated pulmonary hypertension / S.R. John­son, D. Patsios, D.M. Hwang, J.T. Granton // J. Rheum. – 2006. – Vol. 33, N 11. – P. 2347-2350.
  39. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension / M. Williams, C. Handler, R. Akram [et al.] // Eur. Heart. J. – 2006. – Vol. 27, N 12. – P. 1485-1494.
  40. Rosenkranz S. Right heart catheterisation: best practice and pitfalls in pulmonary hypertension /S. Ro­senkranz, R. Ioana // Preston Eur. Resp. Review. – 2015. – Vol. 24. – P. 642-652.
  41. Schwaiger J.P. Screening patients with sclero­derma for pulmonary arterial hypertension and im­plications for other at risk populations // J.P. Schwaiger, D. Khanna, J. Gerry Coghlan // Eur. Resp. Rev. – 2013. – Vol. 22, N 130. – P. 515-525.
  42. Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic che­mokines / P.S. Tsou, B.J. Rabquer, R.A. Ohara [et al.] //Rheum. – 2016. – Vol. 55, N 4. – P. 745-754.
  43. Scleroderma renal crisis accompanied by new-onset pulmonary arterial hypertension: an acute systemic endothelial injury? Case report and literature / T. Di­mitroulas, P. Sarafidis, V. Roma [et al.] // Inflamm. Al­lergy Drug. Targets. – 2010. – Vol. 9, N 4. – P. 313-318.
  44. Serum uric acid as a prognostic predictor in pul­monary arterial hypertension with connective tissue disease / W. Njaman, T. Iesaki, Y. Iwama [et al.] // Inter. Heart. J. – 2007. – Vol. 48, N 4. – P. 523-532.
  45. Shah Ami A. Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hyper­tension / Ami A. Shah, Fredrick M. Wigley, Laura K. Hummers // J. Rheum. – 2010. – Vol. 37, N 1. – P. 98-104.
  46. Steen V. Predictors of isolated pulmonary hyper­tension in patients with systemic sclerosis and limited cutaneous involvement / V. Steen, T.A. Medsger // Arthri­tis Rheum. – 2003. – Vol. 48, N 2. – P. 516-522.
  47. Systemic sclerosis with renal crisis and pulmo­nary hypertension: a report of eleven cases / O.H. Gün­düz, N. Fertig, M. Lucas, T.A. Medsger // Arthritis Rheum. – 2001. – Vol. 44, N 7. – P. 1663-1666.
  48. Tricuspid annular displacement predicts survival in pulmonary hypertension / P.R. Forfia, M.R. Fi­sher, S.C. Mathai [et al.] // Am. J. Resp. Crit. Care Med. – 2006. – Vol. 174, N 9. – P. 1034-1041.
  49. Von Willibrand factor independently predicts long-term pulmonary arterial hypertension / S.M. Kawut, E.M. Horn, K.K. Berekashvili [et al.] // Chest. – 2005. – Vol. 128. – P. 2355-2362.